Close
16/03/2017
​A new class of inhibitors against pain investigated at the ALBA synchrotron
The pharmaceutical company ESTEVE (2,470 people, 916 million Euros income in 2016), the Universitat Autònoma de Barcelona (UAB) and the ALBA Synchrotron joined together to investigate the mechanism of action of new inhibitors against pain developed by the company.

Getting new information about the interactions, active site and mechanism of action of the developed drugs and the therapeutic target may help to the better understanding of the effects of the inhibitors and can provide key information to improve their properties. In that sense, the XALOC ALBA beam line offers a valuable tool for carrying out the corresponding experiments.

As a first step, the research will be carried out at the Protein Production Platform of the UAB to obtain the pure protein complexed with the inhibitors. Secondly, X-ray crystallography studies will be performed at the biolab and in ALBA.

This project is a good example of public-private collaboration that fosters the synergies and relationships between the industrial and academic sectors to advance research and innovation.

More news

30/07/2014 Barcelona among the top 10 cities in the world 24/07/2014 Researchers prove the effectiveness of a new drug against malaria using synchrotron light 17/07/2014 Creation of the Health Technologies Cluster 10/07/2014 An international team of scientists led by researchers from the UAB creates the world's first magnetic hose 03/07/2014 CaixaBank and Oracle set up a Big Data Centre of Excellence in the Barcelona Synchrotron Park 26/06/2014 The Barcelona Supercomputing Center hosts two important new international projects
39 40 41 42 43 44 45 46 47 48 49